JSPR
Jasper Therapeutics, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.16
P/S
0.00
EV/EBITDA
0.20
DCF Value
$1.44
FCF Yield
-491.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-372.2%
ROA
-211.9%
ROIC
-352.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-9.1M | $-0.32 |
| FY 2025 | $0.00 | $-75.8M | $-3.95 |
| Q3 2025 | $0.00 | $-18.7M | $-1.13 |
| Q2 2025 | $0.00 | $-26.7M | $-1.74 |
Analyst Ratings
View AllConsensus
Hold
Target (Consensus)
$41.67
Target (Median)
$55.50
Target Range
$3.00 - $65.00
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
3.09
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.